Kornimate/medical-research-clean huggingface dataset:
reinsertion achilles tendon vs zadek osteotomy in insertional achilles tendinopathy

Conditions: Insertional Achilles Tendinopathy

Summary: the aim of this study is to compare functional outcome and the recovery time of reinsertion of achilles tendon vs zadek osteotomy in insertional achilles tendinopathy.

insertional achilles tendinopathy is characterized by chronic posterior heel pain associated with posterosuperior calcaneal exostosis or intratendinous ossification. the etiologies include retrocalcaneal exostosis, the diseased tendon, enthesopathy, and haglund's deformity. the nonsurgical therapies, such as physical therapy, stretching and strengthening of the gastrocnemius-soleus muscle complexes, nonsteroid anti-inflammatory drugs, and footwear modifications, are chosen as the initial treatment. local injection of the steroid is not recommended because it might lead to increase risk of tendon rupture. surgical intervention is a suitable option when conservative treatment for more than 6 months has failed. open detachment with reattachment of the achilles tendon is a common surgery combined with calcaneoplasty and debridement of the retrocalcaneal bursitis and pathologic achilles tendon. suture techniques using bone anchors have been described to reattach the achilles tendon with excellent results. percutaneous osteotomy is another option, first described by zadek in 1939 which was later modified in 1965. zadek osteotomy is a dorsal closing wedge calcaneal osteotomy that allows the tuberosity of haglund deformity to be brought forward. this operation can change the calcaneus' anatomical length and elevate the distal insertion point of the at. the rationale of a zo was to reduce the impingement between the anterior aspect of the achilles tendon and the superior angle of the posterior calcaneal tuberosity. by shortening the calcaneus and altering the orientation of the achilles tendon fibers it is believed to decrease stress across the tendon at its insertion.

Eligibility criteria:
inclusion criteria: * age range 18 - 65 * insertional achilles tendinopathy without steroid injection, infection, tendon rupture and ankle fracture exclusion criteria: * age \ 65 * general medical contraindications to surgical interventions * calcaneal fracture, subtalar fusion * infection. * pathological tendon rupture * history of steroid injection
influence of flap position following fibreors

Conditions: Periodontitis; Periodontal Diseases

Summary: there is lack of data in literature on keratinized tissue increase after fibreors in relation to primary flap position. this study has been designed as a split-mouth randomized trial to assess the influence of flap position after fibreors. 16 patients were recruited and treated. the placement of the flap 2 mm apically to the bone crest instead at the bone level would be a viable approach to increase kt width without delaying wound healing. the extent of post-operative discomfort/pain was not influenced by primary flap position.


Eligibility criteria:
inclusion criteria: 1) diagnosis of severe chronic periodontitis (corresponding to grade iii or iv according to the actual classification); 2) good general health; 3) full-mouth plaque score (fmps) and full-mouth bleeding score (fmbs) \ 5 mm and persisting bleeding on probing (bop) at posterior natural teeth 3 months after the completion of cause-related therapy exclusion criteria: 1) pregnancy and lactation; 2) smoking \> 10 cigarettes/day; 3) intake of antibiotics in the previous 6 months. in addition, teeth with degree ii or iii mobility, horizontal bone loss higher than 1/3 of the root length or designed as abutment for prosthetic rehabilitation were also excluded from the study.

Keywords: periodontitis flap position soft tissue regrowth
a study to assess how well certolizumab pegol works in patients with moderate to severe plaque psoriasis as part of routine clinical practice

Conditions: Plaque Psoriasis

Summary: the purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.


Eligibility criteria:
inclusion criteria: * the patient is ≥18 years of age at observational point 1 * the patient must have a clinical diagnosis of moderate to severe plaque psoriasis according to the diagnostic criteria used by the physician in routine clinical practice * the patient has an available pasi assessment prior to the first certolizumab pegol dose according to the standard of care * the patient must be newly prescribed with certolizumab pegol * if a patient is participating in an ongoing investigational study, then he/she will not be able to take part in this study exclusion criteria: not applicable

Keywords: plaque psoriasis cimzia certolizumab pegol
keratinocyte skin cancer surgery in the elderly, aged 80 years and over, is effective and safe

Conditions: Postoperative Complication

Summary: as a result of a longer life expectancy and a change in uv exposure, physicians will be facing a growing number of elderly patients with keratinocyte cancer (kc) in fair-skinned populations. the purpose of this study is to better characterize kc surgery in patients over 80 years and older with different comorbid conditions and to investigate the incidence of complications associated with kc surgery. a retrospective monocentric study of patients aged 80 and older, having surgery for kc in university hospital of zurich between january 1, 2022, and december 31, 2022, was conducted. demographics, comorbidities, current medication, treatment type, tumor characteristics, surgical defect size, repair type and complications within 6 months after surgery were analyzed.


Eligibility criteria:
inclusion criteria: * patients aged 80 and older, having surgery for kc in university hospital of zurich between january 1, 2022, and december 31, 2022 exclusion criteria: * presence of a documented rejection.
prone position for non-intubated patients with acute respiratory failure

Conditions: Respiratory Failure

Summary: the study will test the hypothesis that the prone position can be used to reduce the need for intubation and mechanical ventilation in patients with acute respiratory failure.


Eligibility criteria:
inclusion criteria: * bilateral pulmonary infiltrates or unilateral infiltrates involving more than one lobe on cxr * pao2/fio2 \< 40 kpa * rr \> 25, or attending intensivist considering likelihood of intubation \> 50% exclusion criteria: * unsuited for the prone position * fulfilled inclusion criteria for more than 5 days (120 h) * immunosuppression * chronic lung disease * decision of withdrawal or limitation of therapy * pulmonary infiltrates of cardiac origin * decreased gcs level * paco2 \> 10 * attending intensivist considering the patient unsuited for the prone position * bmi \> 33
aprepitant and granisetron for the prophylaxis of radiation induced nausea and vomiting - a pilot study

Conditions: Nausea; Vomiting

Summary: the primary objective of this pilot study is to examine the efficacy of aprepitant given in combination with granisetron for the prevention of delayed-phase rinv in 84 patients receiving a single 8gy of moderately emetogenic palliative rt in the rrrp at sunnybrook odette cancer centre for painful bony metastases from any primary solid tumor. patients will be given a single dose of granisetron 2 mg orally and aprepitant 125 mg on day 0 (at least one hour before on the day of rt) followed by 80 mg of aprepitant once daily in the mornings on days 1 and 2 following the radiation treatment.. secondary objectives include determining the complete rinv prophylaxis rate (acute and delayed phases), the partial emesis control rate, the safety of the combined regime, qol issues, the time to the first emetic event and the time to the first use of rescue medication .


Eligibility criteria:
inclusion criteria: * patients with bone metastases from any primary solid tumor site scheduled to receive a single 8 gy fraction of palliative radiotherapy considered to be moderately emetogenic (an area of at least 80 cm2 in the anterior/posterior direction and located between the level of upper border of t11 and the lower border of l3) in the rrrp at sunnybrook odette cancer centre will be considered eligible. exclusion criteria: * exclusion criteria include having nausea or vomiting 24hrs prior to radiation * having received or being scheduled to receive cranial radiation, moderately or highly emetogenic cytotoxic therapy 7 days prior to, during, or after radiation, receiving corticosteroids (except inhaled or topical), 5ht3 receptor antagonists or nk-1 antagonists or other antiemetic medication, being allergic to study medications, having a kps\<40, being pregnant or of childbearing potential and not using contraceptive measures.

Keywords: nausea vomiting antiemetics radiotherapy radiation-induced nausea and vomiting
comparison of the quality of cpr by professional helpers (emergency physicians / paramedics) during flights

Conditions: Cardiac Arrest

Summary: investigation of the influence of narrowness and unusual circumstances on the cpr-quality

even for paramedics and emergency physicians, the resuscitation of patients with cardiac arrest remains a challenge. previous studies have shown that the cardiac output varies widely even under normal ambient conditions. especially the mean frequenices of cardiac compression varies from 60 to 160/min, as well as the now-flow-time. aim of this study is to investigate how narrowness and movement during a transport affect the cpr-performance. for this, we examine the impact of the common transport options (air and ground) on the outcome-varity on a manikin. the subjects for this study are professional rescuers (emergency physicians / paramedics) who perform a 10 minute als-cpr in either normal circumstances (resuscitation-room) or during transportation.

Eligibility criteria:
inclusion criteria: * emergency physician * paramedic * \> 18 years * \< 60 years exclusion criteria: * pregnant * lay rescuers
double-blind, vehicle-controlled study of the efficacy and safety of sadbe in subjects with recurrent herpes labialis

Conditions: Herpes Labialis; Cold Sore

Summary: this study evaluates the safety and efficacy of sadbe in the prevention of recurrent herpes labialis in adults. two-thirds of the participants will receive a sadbe solution, while the other third will receive only the vehicle as a placebo control. the solutions will be administered topically to the patient's arms. the study will compare a single-arm application versus a two-arm application versus two placebo doses on the arm.


Eligibility criteria:
inclusion criteria: * age ≥18 * clinical diagnosis of herpes labialis, which may be made at the screening visit based on the patient's self-reported history of symptoms. an active herpes labialis outbreak at the time of entry into the clinical trial will neither be required nor will be an exclusion criteria. * self report having four or more episodes of herpes labialis in the past 12 months exclusion criteria: * people that have had treatment with anti viral therapy within 2 weeks before sensitization dose. * pregnant or lactating females. * current or recurrent non-herpetic infection or any underlying condition that may predispose to infection or anyone who has been admitted to the hospital due to bacteremia, pneumonia or any other serious infection. * therapy with glucocorticoid or immunosuppressants at time of recruitment or within past 4 weeks, except for inhaled corticosteroids for asthma or topical steroids in sites other than face. * history of malignancy (except patients with surgically cured basal cell or squamous cell skin cancers) * history of organ transplantation * hiv-positive status determined by history at screening or known history of any other immunosuppressive disease. * severe co-morbidities (diabetes mellitus requiring insulin, chf (ef\<50% at baseline will be exclusionary) mi, cva or tia within 3 months of screening visit, unstable angina pectoris, oxygen-dependent severe pulmonary disease * history of exposure to squaric acid or squaric acid dibutyl ester. * known hypersensitivity to dmso * any condition judged by the investigator to cause this clinical trial to be detrimental to the patient. * subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit. * previous or current participation in a clinical trial of sadbe to treat herpes labialis.
study of topically administered oxybutynin gel in patients with urge incontinence

Conditions: Urge Urinary Incontinence; Urinary Frequency

Summary: the primary objective of the double-blind phase of the study is to compare the effects of two doses of oxybutynin gel to placebo gel. the objective of the open-label extension is to evaluate the extended safety and skin-irritation profile of topically administered oxybutynin gel. the hypothesis is that topically administered oxybutynin gel will decrease (compared to placebo) the number of incontinence episodes per week, average daily urinary frequency, and urinary urgency; increase average urinary void volume; and improve patient quality of life.


Eligibility criteria:
inclusion criteria: * overactive bladder (oab) symptoms of urge and/or mixed ui with a predominance of urge incontinence for at least 3 months * have a history of at least 1 - 2 urge episodes and 8 or more voids per day exclusion criteria: * incontinence that is predominantly stress, insensate, or overflow in nature, or incontinence related to chronic illness, anatomical weakness/abnormalities or concomitant medications * pvr volume \> 200 ml or relative pvr \> 50% of pre-void volume as determined by bladder ultrasound * history of urinary retention, gastric retention, or uncontrollable narrow-angle glaucoma, or patients who are at risk for these conditions
development and evaluation of an adult burn prevention program

Conditions: Burns

Summary: the aim of this study was to evaluate the effectiveness of a targeted burn prevention message on burn safety knowledge and behavior.

flammable liquid burns comprise 23% of admissions to our burn center. this was a project to test the uptake of the message "don't be a flaming fool" delivered via multi-media campaign.

Eligibility criteria:
inclusion criteria: * male 16 years of age or older exclusion criteria * males less than 16 years of age * females

Keywords: prevention burn adult health promotion evaluation media
trop2-targeting nir-ii molecular probe for breast cancer precise surgery

Conditions: Breast Cancer; Sentinel Lymph Node; Margins of Excision

Summary: positive surgical margins are closely associated with local recurrence in breast-conserving surgery (bcs). meanwhile, accurately assessing sentinel lymph node (sln) metastasis is crucial for determining the extent of axillary lymph node dissection (alnd) and minimizing complications. indocyanine green (icg)-based the second near-infrared (nir-ii) fluorescence imaging offers real-time visualization during surgery, potentially reducing positive margin rates and improving sln detection, while the specificity remains a challenge. herein, the investigators will introduce a novel nir-ii probe, ttp-icg, based on a trop2-targeting peptide and an approach which enables rapid differentiation between cancer and para-cancer tissue as well as metastatic and normal lymph nodes. in brief, fresh tissues will be soaked in ttp-icg immediately after resection, and their histological characterization will be determined under nir-ii fluorescence imaging. pathological confirmation will further validate our approach.

after patient enrollment, surgical treatment will be administered based on clinical diagnosis and treatment. during the surgery, excised breast masses or lymph nodes will undergo incubation with ttp-icg following this specific procedure: 1. preparation of the incubation solution: ttp-icg will be dissolved in phosphate-buffered saline (pbs) at room temperature in the dark, with varying concentrations (5, 10, 20 μg/ml). 2. incubation of fresh breast masses or lymph nodes: the freshly excised breast masses or lymph nodes will be immersed and gently agitated in the incubation solution for 3, 5, or 10 minutes. subsequently, they will be rinsed with pbst buffer (pbs with tween 20) for 5 minutes and dried using absorbent paper. 3. acquisition of nir-ii images: nir-ii images and fluorescent intensities will be captured using the "digital precision medicine (dpm)" nir-ii system, optimized with appropriate parameters. 4. pathological diagnosis and data analysis: hematoxylin and eosin staining, along with immuno-histochemistry, will be performed. the subsequent correlation between pathological characterization and fluorescent information will be further analyzed.

Eligibility criteria:
inclusion criteria: * adult patients between 18-75 years of age * female * patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment * good operative candidate * subject capable of giving informed consent and participating in the process of consent exclusion criteria: * patients unable to participate in the consent process * patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc * other conditions that the researcher considers inappropriate to participate in the study

Keywords: nir-ii trop2 surgical navigation breast cancer sentinel lymph node
is real-time cgm superior to flash glucose monitoring in real life study (corrida life)

Conditions: Diabetes Mellitus, Type 1

Summary: the aim of the investigator's study is to compare real-time continuous glucose monitoring (rt-cgm) and flash glucose monitoring (fgm) in adult patients with type 1 diabetes (t1d) in real life practice during 24 weeks of follow-up.


Eligibility criteria:
inclusion criteria: * patients with t1d naive to rt-cgm and fgm * type 1 diabetes for \> 1 year * ≥ 18 years old * csii without automatic functions or mdi exclusion criteria: * previous rtcgm or fgm use * treatment with insulin pump with automatic functions * severe noncompliance * known severe diabetic retinopathy and/or macular edema * lactation, pregnancy, or intending to become pregnant during the study * a condition likely to require mri * use of acetaminophen-containing medication * unwillingness to use the study device for \>70% of time

Keywords: continuous glucose monitoring flash glucose monitoring hypoglycaemia time in range
psg validation study of zensorium biosensing wearable device

Conditions: Sleep Wake Disorders; Healthy

Summary: the objective of this study is to collect data comparing the zensorium biosensing wearable device (zbwd) to polysomnography (psg) in individuals with sleep-wake disorders. zbwd is similar to other wearable devices (e.g., fitbit and apple watch) that use an optical light sensor and tri-axis accelerometer to record steps, activity, sleep/awake states, sleep staging, and statistical variation of pulse pressure to track stress. specifically, it is designed to report sleep duration, non-rapid eye movement (nrem) and rem sleep duration. however, zbwd has not been validated against psg for sleep tracking in healthy controls or in individuals with sleep-wake disorders.

subjects known to have or not have sleep-wake disorder, as well as healthy subjects, will be enrolled if they otherwise meet all the inclusion criteria, and none of the exclusion criteria. subject will be asked to complete several questionnaires and wear the zbwd for 7-days, in an off-site (home) study, followed by a single overnight psg study to compare the zbwd data to the current gold standard of psg. subjects who have completed the study will also be sent a letter thanking them for their participation and offering a summary of the results of their sleep study.

Eligibility criteria:
inclusion criteria: * 1. health status: healthy, or those with sleep-wake disorders exclusion criteria: 1. pregnancy 2. currently smoking 3. any respiratory disorder other than associated with sleep/wake disorder or well-controlled asthma 4. habitual use of medications known to affect respiratory function (e.g. opioids, benzodiazepines, etc). 5. use of medication known to affect pulse pressure (beta blockers) 6. atrial fibrillation 7. tattoos located on wrist
arm and ankle blood pressure cuffs during c-section

Conditions: Supine Hypotensive Syndrome; Cesarean Section Complications; Anesthesia Complication

Summary: this is a single center prospective self-control study to validate the effectiveness of left uterine displacement after subarachnoid block (sab) with simultaneous measurements of blood pressure (bp) on the arm and left ankle during surgery in patients undergoing cesarean delivery (cd) at the ohio state university wexner medical center

in the last three decades, numerous interventions have been studied and implemented into our daily practice, such as pre-loading versus co-loading, phenylephrine versus ephedrine, and phenylephrine infusion versus intermittent boluses. in addition, the effectiveness of left uterine displacement (lud) to improve blood flow and pressure remains unclear. also, there are issues to be addressed on this regard, including: 1. poor placental perfusion from inadequate lud due to the potential impact of supine hypotensive syndrome (shs) secondary to aortocaval compression especially after sab; 2. shivering during cesarean delivery (cd) resulting in inaccurate bp measurements, the incidence of shivering during cd is reported to be 21.9%. it is unclear the impact of shivering during cd on blood pressure (bp) measurements; 3. patient discomfort during bp measurements, calf \> arm \> ankle the investigators are conducting a single center prospective self-control study aiming to validate the effectiveness of lud after sab with simultaneous measurements of bp on the arm and left ankle during surgery in patients undergoing cesarean delivery (cd). in addition, the investigators will determine whether ankle bp correlates more accurately than arm sbp with the incidence of nausea/vomiting and category ii or iii fetal heart tracing and bradycardia after sab and lud under no shivering conditions and the impact of body mass index and antepartum estimation of newborn weight on shs after the sab.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. women undergoing cesarean delivery at the ohio state university wexner medical center under spinal anesthesia 3. american society of anesthesiologists physical status i-iii 4. body mass index during pregnancy ≥ 35 kg/m2 5. able to consent in english language 6. singleton pregnancy exclusion criteria: 1. women undergoing elective cesarean delivery at the ohio state university wexner medical center under anesthesia other than spinal anesthesia (i.e. general and/or epidural anesthesia) 2. prisoners